rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Mark Pruzanski

Director

Company insider

Files Form 4 as: Director, Equillium; President & CEO, Intercept Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
305
Buys
1
Sells
44
Bought
$500K
Sold
$59.8M
Companies
2
Companies where not an officer
1
First trade
16 Nov 2012
Last trade
28 May 2026
Last filed
29 May 2026

Companies traded

Where they are an officer
Intercept PharmaceuticalsDirector, Officer · last 8 Nov 20231 buy · 44 sells
Everywhere else they filed: board seats, 10% stakes, other companies
EQ EquilliumDirector · Biotechnology · last 28 May 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
28 May 2026filed 29 May 2026EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code A—70,000 at $0.00filing
28 May 2026filed 29 May 2026EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code A—70,000 at $0.00filing
21 May 2025filed 23 May 2025EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
14 Feb 2025filed 19 Feb 2025EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code A—12,000filing
14 Feb 2025filed 19 Feb 2025EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code D—12,000filing
14 Feb 2025filed 19 Feb 2025EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code A—24,000filing
14 Feb 2025filed 19 Feb 2025EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code D—24,000filing
14 Feb 2025filed 19 Feb 2025EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code A—20,770filing
14 Feb 2025filed 19 Feb 2025EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code D—20,770filing
14 Feb 2025filed 19 Feb 2025EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code A—20,000filing
14 Feb 2025filed 19 Feb 2025EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code D—20,000filing
22 May 2024filed 23 May 2024EQ Equilliumoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
8 Nov 2023filed 13 Nov 2023Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—332filing
8 Nov 2023filed 13 Nov 2023Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—5,401filing
8 Nov 2023filed 13 Nov 2023Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—1,044filing
8 Nov 2023filed 13 Nov 2023Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—31,506filing
8 Nov 2023filed 13 Nov 2023Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—635filing
8 Nov 2023filed 13 Nov 2023Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—29,865filing
8 Nov 2023filed 13 Nov 2023Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—1,207filing
8 Nov 2023filed 13 Nov 2023Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—38,793filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed45

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.